| NCT ID | NCT03049072 |
| Status | Recruiting |
| Phase | — |
| Sponsor | EBG MedAustron GmbH |
| Condition | Ion Beam Radiation Therapy for Tumor Patients |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,800 participants |
| Start Date | 2016-12 |
| Primary Completion | 2031-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,800 participants in total. It began in 2016-12 with a primary completion date of 2031-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is the prospective and standardized data collection of patients treated with ion therapy at MedAustron.
Eligibility Criteria
Inclusion Criteria: * Patients with tumor disease treated with ion beam therapy at MedAustron * Signed informed consent form Exclusion Criteria: * Comorbidities endangering treatment delivery or study compliance
Contact & Investigator
Yvonne Goy, MD
PRINCIPAL INVESTIGATOR
EBG MedAustron GmbH
Frequently Asked Questions
Who can join the NCT03049072 clinical trial?
This trial is open to participants of all sexes, studying Ion Beam Radiation Therapy for Tumor Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03049072 currently recruiting?
Yes, NCT03049072 is actively recruiting participants. Contact the research team at yvonne.goy@medaustron.at for enrollment information.
Where is the NCT03049072 trial being conducted?
This trial is being conducted at Wiener Neustadt, Austria.
Who is sponsoring the NCT03049072 clinical trial?
NCT03049072 is sponsored by EBG MedAustron GmbH. The principal investigator is Yvonne Goy, MD at EBG MedAustron GmbH. The trial plans to enroll 2,800 participants.